Skip to main content
7 search results for:

Erdafitinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 13-05-2022 | Urothelial cancer | News | Article

    Limited uptake of erdafitinib in real-world setting

    US researchers have found limited use of erdafitinib, the first targeted therapy approved for urothelial cancer, in routine care.

  2. 17-09-2021 | ESMO 2021 | Conference coverage | Article

    Cetrelimab–erdafitinib duo shows promise in advanced urothelial carcinoma

    Adding the novel anti-PD-1 agent cetrelimab to the pan-FGFR inhibitor erdafitinib doubles the response rate in cisplatin-ineligible patients with untreated locally advanced or metastatic urothelial cancer and FGFR alterations, indicate trial data.

  3. play
    18-09-2021 | ESMO 2021 | Conference coverage | Video

    Promising early results for cetrelimab plus erdafitinib reported for advanced UC

    Thomas Powles explains why the interim results of the NORSE trial of first-line cetrelimab plus erdafitinib in FGFR-altered advanced urothelial cancer not only justify its continuance, but also point to the need for larger studies of the combination in this setting. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

  4. 24-07-2019 | Erdafitinib | News | Article

    Erdafitinib shows promising efficacy in advanced urothelial carcinoma

    The pan-FGFR inhibitor erdafitinib could be a treatment option for previously treated patients with locally advanced or metastatic urothelial carcinoma harboring FGFR aberrations, suggest phase II trial results.

  5. 26-04-2019 | FDA | News | Article
    approvalsWatch

    Erdafitinib approved for advanced urothelial carcinoma

    medwireNews : US patients with locally advanced or metastatic urothelial carcinoma with key mutations may now be treated with the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib as a second-line or later therapy.

  6. 20-04-2023 | Urothelial cancer | At a glance | Article

    At a glance: Second and later line immunotherapy for advanced urothelial carcinoma

    Treatment: Cohort 1 – erdafitinib 8 mg/day or vinflunine or docetaxel chemotherapy.

  7. 06-12-2019 | Bladder cancer | Feature | Article

    A closer look at the NCCN patient guidelines for bladder cancer

    Flaig also highlighted the approval by the US FDA of the FGFR inhibitor erdafitinib for muscle-invasive disease harboring FGFR alterations.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.